Caspofungin: a potential cause of reversible severe thrombocytopenia.
Caspofungin is an echinocandin agent approved for the treatment of invasive candidiasis and refractory aspergillosis. Compared with amphotericin B, caspofungin has an improved safety profile, but clinical experience with this agent is still accumulating. A 68-year-old man developed reversible severe thrombocytopenia, possibly due to caspofungin, after being successfully treated for Candida albicans endocarditis. Given the limited clinical experience with caspofungin, continued vigilance for unusual and serious adverse events associated with the drug is imperative.
Lynch
Julia
J
School of Pharmacy, University of Southern California, Los Angeles, California 90033, USA.
Wong-Beringer
Annie
A
D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology; D000077336:Caspofungin; D054714:Echinocandins; D004696:Endocarditis / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D055666:Lipopeptides; D008297:Male; D010456:Peptides, Cyclic / Q000009:adverse effects* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced*; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin